Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Account Payables
Amounts the company owes suppliers for goods and services received.
Evommune, Inc.NYSE: EVMN
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 46.6% from a year ago
Account payables stood at $4.05M at the end of Q1 FY2026, down 46.6% from a year earlier and down 47.8% from the prior quarter.
Context
- Account payables amounted to 1.3% of total assets at the end of Q1 FY2026, down 12.3 pp from a year earlier.
- Account payables increased in 1 of the last 2 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -46.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 7.76M USD
- Year-over-year change
- -6.1%
- 2-year CAGR
- +110.0%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.76M | -6.1% |
| FY2024 | 2024-12-31 | 8.26M | +370.1% |
| FY2023 | 2023-12-31 | 1.76M | — |
Account Payables vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 account payables of $4.05M is the 6th highest of the 10 companies compared; the peer median is $4.28M.
- Its year-over-year change of -46.6% is the 9th highest of 10, against a peer median of +9.6%.
- Account payables amounts to 1.3% of total assets for EVMN, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $131.86M | +10004.4% | -17.6% | 11.2% | |
FTREFortrea Holdings Inc. | Jun 2026 | $54.2M | -41.5% | -28.6% | 2.0% |
| Mar 2026 | $18.81M | +14.6% | +21.0% | 6.5% | |
| Jun 2026 | $9.41M | +9.6% | -15.2% | 0.4% | |
| Mar 2026 | $4.28M | -27.1% | +13.0% | 3.3% | |
EVMNEvommune, Inc. | Mar 2026 | $4.05M | -46.6% | — | 1.3% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $2.29M | +12.3% | -31.3% | 2.2% |
| Mar 2026 | $2.13M | -64.8% | -21.8% | 1.6% | |
| Mar 2026 | $1.65M | -14.5% | -14.2% | 0.6% | |
CLYMClimb Bio, Inc. | Mar 2026 | $860K | +10.7% | +44.6% | 0.6% |
| Peer median (excluding EVMN) | $4.28M | +9.6% | -15.2% | 2.0% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.